Drug Approval | June 17, 2024
Imfinzi approved in the US for endometrial cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Subscribe To Our Newsletter & Stay Updated
